Analgesia Clinical Trial
Official title:
Efficacy of Ultrasound-guided Transversus Abdominis Plane Block in Breast Reconstruction Surgery With Abdominal Myocutaneous Flap: an Observational Prospective Study
NCT number | NCT03699267 |
Other study ID # | 88/561 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 2015 |
Est. completion date | June 2017 |
Verified date | October 2018 |
Source | Instituto Portugues de Oncologia, Francisco Gentil, Porto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Ultrasound (US)-guided transversus abdominis plane block (TAP) has demonstrated favourable
results in lower abdominal surgery. Literature about its efficacy in breast reconstruction
surgery with transversus rectus abdominis myocutaneous (TRAM) flap is still scarce.
In the current study investigators pretend to evaluate the efficacy of US-guided bilateral
TAP block for unilateral breast reconstruction using autologous abdominal graft in women with
breast cancer's history.
Status | Completed |
Enrollment | 107 |
Est. completion date | June 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients of age superior 18 years-old; - Patients scheduled to unilateral breast reconstruction surgery with TRAM flap or partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan was GBA or GBA + TAP. Exclusion Criteria: - Refusal to participate in study; - Inability to sign written informed consent; - Body mass index superior (BMI) 40 kg/m2; - Opioid tolerance (defined as previous consume, minimum period of 2 months, = 50 mg morphine equivalents, per os); - Substance abuse (addiction syndrome) - Renal chronic disease with creatinine clearance < 30 mL/min/1.73m2); hepatic disease (Child-Pugh score of 1, 2 or 3); - Patients subjected to other surgeries within the same operative time - Patients that TAP block was not performed before surgical incision and the dose and volume of ropivacaine wasn't 20 mL, ropivacaine 0.375% - Patients whose systemic analgesic protocol wasn't that adopted by Anesthesiology Department for this kind of surgery |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Instituto Portugues de Oncologia, Francisco Gentil, Porto |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fentanyl consumed/administered during intraoperative time | Based on anaesthesia records, fentanyl administered during intraoperative time was calculated in milligrams per kilogram for each participant. | Investigators recorded this variable for each participant since the date of start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017). | |
Primary | Morphine consumed/administered during post-anaesthesia care unit stay | Based on post-anaesthesia care unit records, quantity, in milligrams, of supplemental morphine administered to each participant was recorded. | Investigators recorded this variable for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017). | |
Secondary | Morphine consumed/administered after discharge from post-anaesthesia care unit discharge until 24 hours since surgery's end | Based on records from Acute Pain Registration, it was recorded, for each participant, total morphine consumed/administered, in milligrams, since post-anaesthesia care unit's discharge until 4th postoperative hour and since 4th until 24th postoperative hour. | Investigators recorded this variable for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017). | |
Secondary | Pain's assessment at rest and on movement | Evaluation of pain at rest and on movement, using a qualitative scale. Investigators used qualitative pain scale adopted in the study site. Scale ranges from 0 to 4. It is defined as: 0 - no pain reported by participant; 1 - slight pain reported by participant; 2 - moderate pain reported by participant; 3 - severe pain reported by participant and 4 - excruciating pain. Pain assessment was recorded, based on records from post-anaesthesia care unit and Acute Pain Registration, for each participant at different moments. At admission and discharge from post-anaesthesia care unit, at 4th postoperative hour and at 24th postoperative hour. |
Investigators recorded these variables for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017). | |
Secondary | Recovery score, at admission and discharge from post-anaesthesia care unit, according to post-anaesthesia care unit's discharge criteria | It was registered for each participant, total score at PACU's admission and discharge according to: Peripheral O2 saturation: 0 - < 85%, 1 - 85-95% and 2 - > 95%; Motor activity: 0 - inability to move, 1 - move 2 extremities; 2 - move 4 extremities; Hemodynamic: 0 - variation of medium arterial pressure (MAP) comparing to pre-anaesthetic evaluation > 40 mmHg or hear rate (HR)<40 or >50 bpm; 1 - variation of MAP comparing to pre-anaesthetic evaluation >40 mmHg or HR<50 or >120; 2 - MAP and HR similar to pre-anesthetic evaluation; Temperature: 0 - body temperature (T)<35ºC; 1 - T 35-35.5ºC; 2 - T 35.5-36ºC; Breathing: 0 - no spontaneous breathing; 1 - dyspnea/respiratory rate (RR) <10 or >20; 2 - eupnea; Consciousness: 0 - nor responding to stimuli; 1 - responding to simple questions; 2 - awake and alert; Nausea/Vomiting: 0 - vomiting; 1 - nausea; 2 - no nausea or vomiting; Pain: 0 - intolerable; 1 - intense; 2 - mild; 3 - no pain. Total score was calculated by summing each score. | Investigators recorded these variables for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017). | |
Secondary | Nausea and vomiting incidence | Based on post-anaesthesia care unit and ward records, it was registered any episodes of nausea or vomiting for each participant until 24th postoperative hour. | Investigators recorded these variables for each participant since the start of the study until its end (since April 2015 until June 2017, 2 years and 2 months). Outcome was globally evaluated for each cohort at the end of the study (June 2017). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05534230 -
Dexmedetomidine for Pain Reduction in CABG
|
N/A | |
Recruiting |
NCT06275698 -
HONEY for the Treatment of POst-Tonsillectomy Pain
|
N/A | |
Recruiting |
NCT04436224 -
Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation
|
Phase 4 | |
Not yet recruiting |
NCT04548323 -
Hypoalgesic Effects of Walking and Running Imagined
|
||
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT04394481 -
Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery
|
Phase 4 | |
Completed |
NCT04690647 -
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
|
N/A | |
Completed |
NCT05034601 -
ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure
|
N/A | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05454202 -
Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
|
||
Recruiting |
NCT04554186 -
Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.
|
N/A | |
Suspended |
NCT04860635 -
Safety of F14 Following Total Knee Replacement
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06393777 -
Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion
|
N/A | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Completed |
NCT02916342 -
Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks
|
Phase 4 | |
Completed |
NCT03206554 -
Local Infiltration Analgesia in Total Knee Arthroplasty
|
Phase 2 | |
Not yet recruiting |
NCT02549118 -
Tenoxicam for Intrapartum Analgesia
|
Phase 2 | |
Not yet recruiting |
NCT02190760 -
Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.
|
N/A | |
Completed |
NCT01789606 -
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
|
Phase 3 | |
Completed |
NCT01299584 -
ULTIVA Post Marketing Surveillance
|
N/A |